Model-informed target product profiles of long acting-injectables for use as seasonal malaria prevention

- _
- 3
- 4

5 Authors:

- 6 Lydia Burgert^{1, 2}, Theresa Reiker^{1, 2}, Monica Golumbeanu^{1,2}, Jörg J. Möhrle^{1, 2, 3}, Melissa A. Penny*^{1, 2}
- 7 ¹ Swiss Tropical and Public Health Institute, Basel, Switzerland
- 8 ² University of Basel, Basel, Switzerland
- 9 ³ Medicines for Malaria Venture, Geneva, Switzerland
- 10

11 **1. Abstract**

12 Seasonal malaria chemoprevention (SMC) has proven highly efficacious in reducing malaria incidence. However, the continued success of SMC is threatened by the spread of resistance against one of its main 13 14 preventive ingredients, Sulfadoxine-Pyrimethamine(SP), operational challenges in delivery, and 15 incomplete adherence to the regimens. Via a simulation study with an individual-based model of malaria 16 dynamics, we provide quantitative evidence to assess long-acting injectables (LAIs) as potential alternatives 17 to SMC. We explored the predicted impact of a range of novel preventive LAIs as a seasonal prevention 18 tool in children aged three months to five years old during late-stage clinical trials and at implementation. 19 LAIs were co-administered with a blood-stage clearing drug once at the beginning of the transmission 20 season. We found the establishment of non-inferiority of LAIs to standard 3 or 4 rounds of SMC with SP-21 amodiaquine was challenging in clinical trial stages due to high intervention deployment coverage. 22 However, our analysis of implementation settings where the achievable SMC coverage was much lower, 23 LAIs with fewer visits per season are potential suitable replacements to SMC. Suitability as a replacement 24 with higher impact is possible if the duration of protection of LAIs covered the duration of the transmission 25 season. Furthermore, optimizing LAIs coverage and protective efficacy half-life via simulation analysis in 26 settings with an SMC coverage of 60% revealed important trade-offs between protective efficacy decay 27 and deployment coverage. Our analysis additionally highlights that for seasonal deployment for LAIs, it 28 will be necessary to investigate the protective efficacy decay as early as possible during clinical 29 development to ensure a well-informed candidate selection process.

31 **2. Background**

32 Children carry the majority of the global malaria burden, with an estimated 67% of all malaria-related deaths (272 000 in 2019) occurring in those under 5 years of age ¹. In addition to effective and timely 33 treatment, prevention through vector control or drug-based prophylaxis has proven to be an effective 34 35 approach, reducing incidence and mortality². Especially in seasonal malaria transmission settings, where 36 malaria transmission is linked to the rainy months, well-timed preventive malaria interventions that protect 37 from infection during the transmission months can ease a substantial amount of malaria burden¹. The WHO 38 recommended seasonal malaria chemoprevention (SMC) with monthly Sulfadoxinehas Pyrimethamine+Amodiaquine (referred to as SMC-SP+AQ) for children aged between 3 months and 5 39 years during the malaria transmission season since 2012³. SP+AQ provides a two-stage effect: while AQ 40 clears existing blood-stage infections, the long clearance half-life of SP prevents new infections. The impact 41 42 of SMC in seasonal settings has been widely demonstrated, achieving a protective efficacy of roughly 80% 43 against clinical episodes in a trial in Burkina Faso⁴, a reduction in incidence by 60% in routine implementation in Senegal (80% deployment coverage of all eligible children)⁵, and a reduction in the 44 45 proportion of positive tests by 44% in routine implementation in Mali⁶.

46 Despite its potential, poor adherence and the spread of drug resistance limit the effectiveness of SMC. 47 Additionally, the monthly delivery of SMC-SP+AQ (one day of SP and three days of AQ) throughout the 48 transmission season is relatively expensive, due to human resources and especially due to operational 49 constraints during the rainy season⁷. Consequently, in 2019, only 62% of children living in SMC-eligible areas in the Sahel subregion received SMC¹. Throughout the transmission season, coverage subsequently 50 51 decreased by 6% in Guinea⁸ and 20% in Mali⁹. Investigation of the adherence to the 3x AQ regimen within one treatment course in a clinical trial in Niger showed that only 20% of children received the full regimen 52 ¹⁰. Additionally, the spread of resistance markers against SP was reported with increasing SMC deployment 53 ^{11, 12}, impacting the eligibility of regions for SMC ¹³ as well as the protective efficacy after implementation 54 14. 55

56 The need for alternative prevention tools that simplify deployment and possess a reduced risk of resistance 57 is pressing. In the absence of an effective vaccine, long-acting injectables (LAIs) with an anti-infective 58 effect could provide an alternative seasonal prevention tool by simplifying the deployment and reducing the risk of resistance through decreased selection pressure for SP resistance ¹⁵. Current candidate LAIs 59 include small molecule drugs ^{16,17} or monoclonal antibodies (mAbs) ^{18,19} that target the sporozoite stage or 60 liver stage of the malaria parasite, thereby serving as anti-infectives. The successful development of a LAI 61 62 entails the definition of appropriate product profiles and use cases which are specified in Target Product 63 Profiles (TPPs). Precisely, these specifications include LAI efficacy and safety prerequisites as well as delivery modalities ¹⁵. TPPs are living documents and therefore continuously updated as new evidence for 64 65 product requirements becomes available.

- To justify the implementation of LAIs under the use case of seasonal malaria prevention, non-inferiority to the existing intervention of SMC-SP+AQ must be met ⁴. For new tools with new modes of action and/or deployment modalities, proving non-inferiority to the standard of care is a crucial step and is usually established in non-inferiority clinical trials conducted at late stages of tool development. Currently, it is not yet known what clinical studies will be required for LAIs. In absence of efficacy data on LAIs, it is at the current stage impossible to obtain insights about the circumstances in which LAIs have the potential to be
- non-inferior. *In silico* modelling and simulation approaches of malaria transmission and control, allow the

quantification of the impact of varying tool specifications in relation to varying operational and setting constraints which would not be feasible in real life clinical trials. They thus allow for the exploration of the potential to meet non informative ariteria. In the channel of non informative ariteria et the carly stores of

- 75 potential to meet non-inferiority criteria. In the absence of non-inferiority evidence at the early stages of
- 76 development, modelling and simulation approaches therefore provide a quantitative basis to further inform
- decision making. They guide tool development from the early stages by predicting potential public health
- ⁷⁸ impact (Fig. 1a) ²⁰ and understanding non-inferiority criteria prior to clinical trial planning.

79 Here, we investigate the potential public-health impact for various use cases of LAIs by conducting an in 80 silico simulation analysis examining product properties and operational modalities supporting LAI implementation as a seasonal malaria prevention tool. Accordingly, in the simulated scenarios, LAIs were 81 82 delivered to children under five once at the beginning of the transmission season with an antimalarial in 83 settings currently approved for SMC deployment. Their protective effect was then compared to SMC-84 SP+AO administered three or four times per season in monthly intervals. By combining disease modelling 85 and simulation experiments with machine learning approaches, we efficiently explored the large space of 86 possible parameter values describing intervention and transmission setting characteristics and analyzed 87 trade-offs between tool characteristics and operational constraints in a variety of transmission settings²⁰. We conducted our malaria transmission simulations using OpenMalaria, an established individual-based 88 stochastic simulation platform of malaria transmission and control^{21 22}. Based on this approach, we defined 89 90 a quantitative framework to assess the influence of tool properties and operational constraints on the impact 91 of SMC and LAIs. Using this framework, we investigated two malaria transmission settings based on the 92 malaria transmission profile in Senegal and Mali and assessed public health impact for a plethora of 93 different tool properties, deployment coverages and over multiple transmission intensities. Our analysis 94 was carried out along the clinical development pathway from late clinical trials through to implementation 95 of future LAIs as an SMC replacement. By understanding the main drivers of impact to reach a pre-defined 96 health goal in implementation stages and under operational constraints, we provide an assessment of 97 endpoints in clinical trials of newly developed LAIs and identify efficacy requirements for further 98 development.

99 **3. Materials and Methods**

100 The impact of novel anti-infective LAIs depends on the tool properties defining their efficacy profile, as 101 well as on the operational constraints and the respective underlying malaria epidemiology, that influence tool suitability for implementation in a given setting (Fig. 1a). We investigated the influence of tool 102 103 properties over a large range of specified protective efficacies, as well as operational considerations 104 (coverage of children) in several implementation settings varying in seasonality and access to healthcare. 105 The drivers of predicted impact for preventive LAIs were analysed along their clinical development from 106 clinical trials to implementation (Fig. 1b) and compared to current standard of care (SMC-SP+AQ). 107 Accordingly, we defined two analysis stages: in the *clinical trial stage*, we investigated the maximum 108 incidence reduction and the ability to establish non-inferiority to SMC-SP+AQ over one malaria season 109 (Fig. 1 b, panel 1). In the *implementation stage*, we replaced SMC-SP+AQ with LAIs after five years of 110 implementation at varying coverages, and we inferred the minimal LAI coverage at which LAIs are 111 equivalent (non-inferiority) in public-health impact (incidence reduction) to a continued implementation of 112 SMC-SP+AQ (Fig. 1b, panel 2).

113 We adapted a previously developed framework to inform TPPs of new interventions against infectious 114 diseases 20 . First, a set of simulated scenarios was defined. These were characterized by the delivery

- 115 modality, tool specifications, and settings in which a concrete health target was analysed (in our case,
- 116 incidence reduction). Second, a set of disease scenarios were simulated randomly over the entire parameter
- 117 space to evaluate the health outcomes. The resulting database of simulations was used to train a Gaussian
- 118 process emulator (GP), that predicts the health outcome given a set of input parameters. Third, the emulator
- 119 was employed to perform sensitivity analysis and optimisation of tool properties with respect to health
- 120 outcomes. This analysis allowed us to define the optimal product characteristics of a LAI that maximises
- 121 the chance of achieving a desired health goal.

122 Malaria disease transmission model

- We explored the dynamics of a preventive LAI against malaria using *OpenMalaria*, a stochastic, individualbased simulator of malaria infection in humans linked to a deterministic model of the mosquito feeding cycle ^{23,24}. *OpenMalaria* accounts for heterogeneity within a human population on multiple levels including host exposure, susceptibility and immune response ^{21,25,26}. The model allows the investigation of interventions against malaria at multiple points in the malaria life cycle (e.g. vaccines ²², insecticide treated bed-nets, and reactive case detection ²⁷) while monitoring a variety of health outcomes (e.g. prevalence, incidence, mortality) ²⁸.
- 130 Simulated disease scenarios

Using *OpenMalaria*, we simulated a range of transmission settings (Fig. S1) and assumptions for the implementation of SMC and LAIs as a seasonal infection prevention intervention replacing existing prevention with SMC-SP+AQ. These assumptions are with regards to the properties of the setting (seasonality and intensity of transmission), health system (access to care and treatment of clinical cases), new and replacement intervention (Table 1).

The intervention age-group consisted of children between 3 months and 5 years of age (accounting for ca. 136 137 16% of the total population). The intervention age-group was chosen according to WHO recommendations ³, although some countries have implemented SMC for children up to 10 years old ²⁹. We assumed a total 138 population of 10,000 individuals to capture transmission settings within health facility catchment areas with 139 an age-structure that represents a realistic age-distribution for African malaria-endemic settings ³⁰. Access 140 141 to treatment, defined as the percentage of the whole population who seek care for a symptomatic malaria 142 episode, was chosen to represent settings with low or high health systems strength. The probability of symptomatic cases to receive effective treatment within two weeks from the onset of symptoms (E_{14}) was 143 144 set to 10% in low access to health-care settings and 50% in high access to health-care settings ³¹. The malaria seasonality profile, mosquito species and timing of interventions were parameterised to reflect those 145 146 of Mali or Senegal, two countries in the Sahel region where SMC is implemented and clinical trials for 147 malaria interventions are conducted frequently. In Mali, the malaria season is longer, starting in August and 148 lasting until November (long season), and SMC is generally four monthly doses. In contrast, the malaria 149 season in Senegal is only three months long, with a sharper profile (short season) and SMC is three doses 150 one month apart (Fig. 1a, Table 1, Figure S2). Malaria prevalence in Senegal is generally low, with the

- highest *P. falciparum* prevalence in 2-10 years old (PfPR_{2-10y}) in the southern regions being around 8%.
- However, the PfPR_{2-10v} in Mali is around 80% in the south of Mali but very low in the North 32 .

153 To develop a broader understanding of the influence of transmission intensity on LAI impact, we simulated

154 a range of initial incidence settings capturing the transmission heterogeneity of these two malaria-endemic

155 countries (Figure S1, Table S1). The simulated transmission intensity of each setting was defined by the

- 156 entomological inoculation rate (EIR) modelled as the average annual number of infectious bites received
- by an individual, and the corresponding simulated $PfPR_{2-10y}$ (Table S1, Fig. S1). The protective efficacy of
- 158 SMC-SP+AQ was implemented as being fully effective (no prevalent resistance against SP) or reduced
- 159 duration of protection (prevalent resistance against SP).

160 Over all simulation experiments, the input parameter space for the protective efficacy and its decay, and 161 the intervention coverage are as defined in Table 1. Parameters were randomly sampled using Latin 162 hypercube sampling ³³ by drawing 1500 parameter sets for each setting, with 5 stochastic realizations

163 (simulation replicates) for each point. All simulations were performed using *OpenMalaria* version 38. The

source code and comprehensive documentation for *OpenMalaria*, including a detailed model of demography, transmission dynamics and interventions is available at ³⁴.

166 **Delivery: clinical trial and implementation assumptions**

167 In our study, LAIs were implemented as anti-infective entities in the form of mAbs or small molecule drugs,

168 that prevent the development of blood-stage malaria through action on malaria parasites in sporozoite or

169 liver stages. We assumed administration once at the beginning of the transmission season in combination

170 with an artemisinin combination therapy that cures prevalent blood-stage malaria infections with a 100%

171 cure rate. SMC-SP+AQ was administered monthly: three times per season in Senegal like settings (short

- 172 *season*) and four times per season in Mali like settings (*long season*) as recommended by the WHO³ (Fig.
- 173 S2). We assume a decrease in SMC coverage by 3% between treatments (ca. 10% over a four-doses
- 174 treatment regimen), therefore lying between the two extremes of observed coverage decrease^{8,9}.

The *clinical trial stage* (Fig. 1b, panel 1) was simulated in the high case management setting to account for awareness of malaria symptoms. Initial deployment coverage levels for both, SMC and LAI, were set to 100%. Follow up visits, in the form of active case detection, were implemented two weeks after every administration round of SMC-SP+AQ in both trial arm. In addition to fully effective SMC-SP+AQ, we investigated a reduced length of protection by prevalent resistance against SP in the *clinical trial stage*.

- 190 In the implementation starses (Fig. 11, and 12) are explanated in the fig. (11)
- 180 In the *implementation stages* (Fig. 1b, panel 2), we analysed the impact of switching seasonal malaria 181 prevention strategies from SMC-SP+AQ after five years of implementation to LAIs. After five years of
- 182 LAI implementation, the cumulative clinical case incidence was compared to a control setting (no
- 183 switching). LAIs and SMC-SP+AQ were implemented with varying coverages between 40-100 %.
- 184 Intervention cohorts, defined by the coverage in the intervention age group, were specified at the beginning
- 185 of a transmission season for the whole season. An exemplary illustration of LAI and SMC-SP+AQ
- 186 implementation is provided in Fig. S4.

187 Intervention characteristics: SMC and LAI properties

188 As the decay of efficacy of LAIs is not yet known, we explored a range of possible scenarios. In both the

189 clinical and implementation analysis, the prevention of infection by LAI was modelled as pre-erythrocytic

- 190 protection from infection E(t) over time defined by the initial protective efficacy E_0 [%], protective efficacy
- 191 half-life of decay L and shape parameter k (Fig. S3). The decay shapes of protective efficacy were chosen
- 192 such that they represent multiple development possibilities: exponential-like decay (referred to as
- 193 exponential LAIs), malaria vaccine-like decay, namely biphasic-like decay ^{35,36} (referred to as bi-phasic

LAIs) and sigmoidal-like decay (referred to as *sigmoidal LAIs*). The protective efficacy decay over time
 E(t) for exponential and bi-phasic LAIs was modelled as either Weibull-like decay:

196
$$E(t) = E_0 e^{-\left(\frac{t}{L}\right)^k \log(2)}$$
, Eq. 1

197 where k =1 yields *exponential LAIs* and k=0.69 yields *bi-phasic LAIs*. *Sigmoidal LAIs* were defined by the 198 following Hill equation with k=8.

199
$$E(t) = E_0 \frac{1}{1 + (\frac{t}{l})^k}$$
. Eq. 2

200 The individual protection profile over time after one administration of SMC-SP+AQ, was parameterized using published clinical trial results⁴. The protection profile in preventing infections is not well understood 201 ³⁷, and usually the protective efficacy of SMC-SP+AQ was assessed in clinical studies in terms of 202 population survival estimates, risk reductions or a reduction in incidence ^{9,38}. To compare the impact of 203 204 novel LAIs with SMC-SP+AQ, we parameterized the protective efficacy of SMC-SP+AQ to data from a clinical non-inferiority trial conducted in Burkina Faso⁴. Our parameterization approach employs a 205 Gaussian process regression model ³⁹ to determine the model parameters that reproduce the clinical trial 206 207 data via minimization of the residual sum of squares between the observed and simulated SMC-SP+AQ 208 protective efficacy. A detailed description of the parameterization process is given in the Supplementary 209 Information. Scenarios assuming SP resistance, the effect of resistance against the SMC component SP was 210 implemented by decreasing the SMC half-life of protection from 32 days to 20 days. The lower protection 211 half-life due to resistance can be modeled as an increase in the drug concentration inhibiting the parasite growth by 50% (IC₅₀). Because SP has a long clearance half-life ⁴⁰, we assume no impact of resistance on 212 the initial efficacy. 213

214 Health target: endpoints to assess impact of LAI

The health targets analysed in this study were based on incidence reduction by LAIs, clinical cases averted by LAIs compared to SMC, and non-inferiority with regard to clinical burden in the modelled clinical trials.

217 Clinical cases per person in the intervention age group $(cpp_{0.25-5y, int})$ over the clinical trial length (Fig. 1a)

 $(cpp_{0.25-5y, int})$ or in the last implementation year $(cppy_{0.25-5y, int})$ (Fig. 1b) were calculated over the whole

219 population at risk in the intervention age-group ($N_{int,0.25-5y}$).

220
$$cpp_{0.25-5y,int} = \frac{total \, cases}{N_{0.25-5y,int}}$$
 Equ. 3

221 The incidence reduction percentage inc_{red} was calculated via the cumulative incidence in the year before 222 trial implementation cpp_{cont} and the cumulative incidence during the clinical trial cpp_{int}

223
$$inc_{red} = \frac{cpp_{0.25-5y,cont} - cpp_{0.25-5y,int}}{cpp_{0.25-5y,cont}} \times 100$$
 Equ. 4

Survival analysis on the number of clinical cases per person *cpp_{int}* was performed to analyse the establishment of non-inferiority of LAIs to SMC–SP+AQ as described in ⁴¹. The impact of a LAI is assumed to be non-inferior to SMC–SP+AQ if the upper limit of the derived 95% confidence interval of the hazard ratio between SMC–SP+AQ and LAI lies below the upper limit for non-inferiority. This limit is informed by the survival estimate of SMC–SP+AQ and the desired margin of non-inferiority. We assumed a margin

of non-inferiority of 5%. More information about the non-inferiority analysis is provided in theSupplementary Information.

Additionally, the intervention impact defined as clinical incidence difference between SMC-SP+AQ clinical cases per person per year $cpp_{0.25-5y}$, $_{SMC}$ and LAIs $cpp_{0.25-5y}$, $_{LAI}$ was compared using the relative difference $diff_{cpp}$ as an indicator for the malaria burden.

- 234
- 235

$$diff_{cpp} = \frac{cpp_{0.25-5y,SMC} - cpp_{0.25-5y,LAI}}{cpp_{0.25-5y,SMC}}$$
Equ. 5

236 Gaussian process emulator approach to predict intervention impact

237 To perform a fast and efficient search of the parameter space of LAI properties, we used a database of 238 OpenMalaria simulations to train heteroskedastic GPs for each LAI efficacy decay type in each seasonal and transmission intensity setting (R-package hetGP, function mleHetGP, Version 1.1.2.)⁴². The input 239 parameters of the GPs in the *clinical trial stage* consisted of the tool properties including initial protective 240 efficacy and protective efficacy half-life. In the *implementation stage*, the input parameters additionally 241 242 included the respective SMC-SP+AQ and LAI deployment coverage. To define the covariance structure of 243 the Gaussian process models, we used a Matérn kernel with smoothness parameter 5/2 accounting for the high variability in the parameter space ⁴². The trained GPs were then used to predict the number of cases 244 245 per person per year and the metrics related to the non-inferiority analysis (Table S2) for any point in the 246 parameter space. Emulator performance was ascertained by testing on a 20% holdout set after training on 80% of the data ²⁰ (Table S2). 247

248 Sensitivity analysis

249 We identified the main drivers of intervention impact via a global sensitivity analysis, performed using 250 decomposition of variance via Sobol analysis on the emulator output predictions. We conducted an EIR-251 stratified sensitivity analysis to assess the potential change in drivers of impact over the whole transmission range. Within the pre-defined parameter space, the total effect indices quantify the interactions between 252 253 individual parameter contributions to the emulator output variance ⁴³. The total effect indices were 254 normalized to obtain the relative importance of each parameter through division by their sum. The total 255 effect indices were estimated with a Monte Carlo sampling approach using the function soboljansen in the 256 R-packages sensitivity (version 1.16.2) with 500 000 sampled points and 1000 bootstrap replicates.

257 Intervention properties and coverage optimisation

258 In the *clinical trial stage*, we discretized the space of the initial protective efficacy and protective efficacy 259 half-life of LAIs within the range of plausible values (Table 1), yielding a two-dimensional grid of 260 parameter value combinations. At each grid point, we used the GP emulators to estimate the upper limit of 261 the confidence interval of the hazard ratio between the survival estimates in the SMC and LAI arm and the 262 non-inferiority margin and check if non-inferiority could be established for the given combination of 263 parameter values (cf. Non-inferiority Analysis in Supplementary Material). The contours of the resulting non-inferiority surface yielded the thresholds of the minimal initial protective efficacy and protective 264 265 efficacy half-life needed to establish non-inferiority across different transmission settings (Fig. 3).

In the *implementation stage*, we additionally determined the minimum required LAI coverage and half-life at which non-inferiority to SMC-SP+AQ could be established. At each grid point, we conducted a

268 constrained optimization, translating the non-inferiority condition into an inequality constraint by requiring

the difference between the upper limit of the confidence interval and the non-inferiority margin to be

270 positive. The optimization was conducted using an augmented Lagrange method (gosolnp, R-package

Rsolnp, Version 1.16) with a minimum of 3 starting values and 200 simulations. To determine the benefits

of reallocation of resources from reduced visits within a season towards increasing deployment coverage,

273 we compared the number of cases per person per year in a simulation with SMC implemented at a given

coverage to the number of cases per person per year with LAI at a coverage that was 20% higher than the

275 optimal coverage.

4. Results

278 Decay shape and duration of protective efficacy influence LAI impact

We assessed the obtained malaria incidence reduction in the simulated scenarios of the *clinical trial stage* at high deployment coverage (100%) and found that the decay shape of LAI protective efficacy and protection half-life play an important role in achieving a targeted incidence reduction (Fig. 2) in each simulated clinical trial scenario. Additionally, we identified the parameter space in which a certain incidence reduction cannot be achieved following LAI deployment under different setting assumptions (below each curve in Fig. 2).

- In settings with a more extended transmission season (Fig. 2 b, d and f), a longer LAI half-life is required
- to reach the same predicted impact compared to the shorter season settings (Fig. 2 a, c, and e). A steeper
- 287 initial decrease of initial protective efficacy (Fig. 1a and Fig. S3) led to lower estimated incidence reduction,
- 288 with *bi-phasic LAIs* exhibiting the lowest predicted impact (Fig. 2 c and d), followed by *exponential LAIs*
- 289 (Fig. 2 a and b). The predicted impact of sigmoidal LAIs was largely determined by their half-life compared
- 290 to initial protective efficacy: an initial decrease in protective efficacy would require only a marginal increase
- of the half-life needed to reach the desired incident reduction (Fig. 2 e and f). In contrast to exponential
- 292 (Fig. 2 a and b) and *bi-phasic LAIs* (Fig. 2 c and d), where the force of infection increased the required
- 293 minimum half-life of protective efficacy, the required minimum half-life for sigmoidal LAIs was not
- significantly increased by the force of transmission (Fig. 2 e and f). A longer malaria transmission season
- 295 (Fig. 2 b, d, and f) was predicted to increase the half-life requirements to reach a desired incidence reduction
- for all LAIs. In these longer transmission season settings, a predicted incidence reduction of over 80% was
- 297 not possible for *exponential* and *bi-phasic* LAIs.
- 298 Fig. 2 shows the exemplary extraction of minimum essential efficacy properties for a LAI with a given half-
- 299 life. For example, if the half-life of protective efficacy of a LAI was assumed to be 150 days, we predicted
- 300 that an initial protective efficacy of 88%, 96%, and 76% was required for exponential, bi-phasic and
- 301 sigmoidal LAIs, respectively (Fig. 2 a, c and e) to reach a clinical incidence reduction of 60% (short malaria
- 302 transmission season, initial cases per person per year_{0.25-5y} of 2.8).

303 Establishing non-inferiority of LAIs to SMC-SP+AQ in clinical trials is difficult

304 In the SMC-SP+AO arm of the simulated *clinical trial stages*, we found a predicted mean achievable 305 incidence reduction of approximatively 90 % in Mali and Senegal-like seasonal settings (Table S 3). Our 306 non-inferiority analysis (Fig. 1b, panel 3) demonstrated that the predicted establishment of non-inferiority 307 of sigmoidal LAIs to SMC-SP+AO under the assumption of 100% initial deployment coverage could only 308 be met with LAI efficacy over 90% in both seasonal settings and half-life over 62 days in Senegal-like 309 (short season) and 88 days in Mali-like (long season) seasonal transmission patterns (Fig. 3). In agreement 310 with the analysis of attainable incidence reduction (Fig. 2), the predicted establishment of non-inferiority 311 was more feasible in settings with a shorter transmission season and lower initial malaria incidence (Fig. 3 312 a). For settings with a lower initial incidence (between 0.5 and 1 initial cases per person per year_{0.25-5v}), the 313 parameter space where non-inferiority could be established varied more than in higher initial incidence 314 settings. If resistance against SP was prevalent, which we modelled as a shorter duration of protection 315 through a decrease in protective efficacy half-life to 20 days (from 32 days), sigmoidal LAIs were predicted 316 to be non-inferior in a wider range of tool property combinations (Fig. 3, c and d). Nevertheless, noninferiority could not be established in any setting for any parameterization of exponential and bi-phasic 317

- 318 *LAIs* under clinical trial coverage assumptions. We conclude that the efficacy decay profiles of LAIs play
- an important role for reaching the defined incidence reduction goals and establishing non-inferiority to
 SMC-SP+AQ.

321 The influence of protective efficacy half-life changes over the parameter space

Moving from clinical field trials towards *implementation stages*, where LAIs are administered as a replacement for SMC-SP+AQ (Fig. 1 b, panel 2), we analyzed the influence of underlying LAI efficacy properties and deployment coverage on resulting intervention impact and non-inferiority to SMC-SP+AQ.

- 325 Our sensitivity analysis via decomposition of variance (Fig. 4) indicate that the influence of half-life of
- 326 protective efficacy depends on the length of the transmission season in *implementation stages*. An increase
- in initial efficacy (Fig. 4 d) and deployment coverage (Fig.4 e) resulted in a linear increase in predicted
- impact. In contrast, the influence of the protective efficacy half-life changed over the parameter space (Fig.
 4 a, b and c), with a much steeper influence for changes in lower half-life ranges. We found a change in the
- main source of variance of the impact of *sigmoidal LAIs* with increasing protective efficacy half-life (shown
- in Fig. 4 a and b for a half-life threshold of 90 days). For instance, if the LAI half-life was less than 90 days
- 332 (Fig. 4a), the protective efficacy half-life and deployment coverage shared almost equal proportions of
- attributable variance, accounting for 38 % to 52% of variance while the initial protective efficacy
- 334 contributed between 7% to 19%, depending on transmission intensity. However, for half-lives greater than
- 335 90 days (Fig. 4 b) the importance of deployment coverage increased from 54% to 85% and importance of
- the initial protective efficacy from 14% to 38 % (in these results we assumed LAIs of less than 70% initial
- 337 protective efficacy are unlikely to be developed). In contrast, the relative importance of the protective
- efficacy half-life decreased to around 2% to 12%. In settings with a longer malaria transmission season
- 339 (Fig. S6 a, d, g), a sharper initial decrease in clinical incidence was predicted for a larger range of protective
- efficacy half-life than for shorter transmission seasons (Fig. S5 a, d, g). Overall, this demonstrates the
- 341 potential to explore how the impact determinants and their importance change based on efficacy duration
- 342 cut-offs compared to length of transmission season or alternative deployment.

343 Trade-offs between enhancing duration of protection and implementation coverage

344 These results illustrate the importance of setting-specific trade-offs between enhancing tool properties or

- 345 improving implementation coverage (Table 2). For example, increasing the half-life of a sigmoidal LAI
- 346 with an initial efficacy of 90% from 49 days to 63 days reduced the predicted required LAI coverage to
- 347 establish non-inferiority to SMC-SP+AQ in implementation (60 % coverage) by 20 % (from 100 % to 80
- 348 %) in a setting with an initial clinical incidence of 1.4 cases per person per year_{0.25-5y}. Furthermore, in
- 349 settings with relatively high levels of initial clinical malaria incidence and corresponding high transmission
- intensity, namely cases per person per year_{0.25-5y}>2.4 and EIR>150, a change in dynamics to establish non-
- inferiority was observed. In these settings, we predicted LAIs will likely fail to sufficiently protect the
- 352 targeted population from clinical malaria even at very high deployment coverage (Fig. S4). Therefore, we
- 353 were unable to assess the required half-life of protective efficacy of LAI for high transmission settings.

For SMC-SP+AQ, we estimated that an additional 13 % to 29 % in incidence reduction could be achieved by increasing the coverage from 62% to 100%, dependent on initial clinical incidence before implementation (Fig. S7). However, achieving high levels of SMC coverage at implementation is

357 challenging^{5,6}, and increasing levels of coverage are associated with increasing costs.

As information on costs of LAI (costs of goods and supply chain) are not available as of now, we were 358 359 unable to include detailed economic analysis in the assessment of LAIs in *implementation stages*. The main cost drivers of SMC-SP+AQ are deployment costs (remuneration of health care workers) and cost of goods 360 ^{44,45}, with deployment costs increasing non-linearly with higher coverage. Therefore, we determined the 361 minimal LAI coverage at which non-inferiority to SMC-SP+AQ (assuming initial SMC deployment 362 363 coverage of 60%) was established, stratified by initial clinical incidence before implementation (Fig 5 and 364 Fig S8 and S9). We found that the parameter space where non-inferiority could be established shrank with 365 increasing baseline malaria incidence (Fig. S8 and S9). With regard to seasonality, LAIs were more likely 366 to be non-inferior in shorter malaria transmission settings in the *implementation stage* (Fig. S7 and Fig. S8). 367 In settings with a high initial clinical incidence (EIR=150, Table S1), LAI coverage could not be optimized 368 to be non-inferior to SMC-SP+AO at 60% coverage because LAIs were unable to prevent malaria cases 369 even at very high coverage levels (Fig. S4d). Overall, the optimisation of LAI coverage in settings with a 370 limited SMC-SP+AQ coverage illustrates the potential of LAI implementation in non-optimal coverage 371 settings.

372 While non-inferiority could only be established in a small part of the parameter space of *sigmoidal LAIs* in

373 long seasonal transmission settings (Fig. 3b), it is possible to increase the potential area of applicability of

374 sigmoidal LAIs by optimising their deployment coverage (Fig. 5a, initial cases per person per year_{0.25-}

 $_{5y}$ =1.4). Deploying a sigmoidal *LAI* at 46% coverage with a half-life of 150 days and initial efficacy of 100% is sufficient to establish non-inferiority over SMC-SP+AO at 60% coverage (Fig. 5 b). In contrast,

sigmoidal LAIs with a half-life of 70 days and initial efficacy of 70 % require a deployment coverage of

378 95% in order to be non-inferior (Fig. 5 e). For sigmoidal LAIs we found that increasing the deployment

379 coverage over the estimated minimum required coverage to establish non-inferiority results in potential

380 gains in terms of clinical incidence reduction compared to SMC-SP+AQ (Fig. 5 b to e).

Additionally, we found that even though non-inferiority of *exponential LAIs* to SMC-SP+AQ could not be established in *clinical trial stages*, coverage optimisation in *implementation stages* reveals their applicability. Deploying an *exponential LAI* at 52% coverage with a half-life of 150 days and initial efficacy of 100% was sufficient to establish non-inferiority over SMC-SP+AQ at 60% coverage (Fig. S10b) and a half-life of 100 days and initial protective efficacy of 90% requires a deployment of 78% to establish noninferiority (Fig. S10c). *Exponential LAIs* with a half-life of 70 days and initial efficacy of 70% were always inferior to SMC-SP+AQ at a coverage of 60% (Fig. S10e).

388 **5. Discussion**

389 The effective prevention of clinical malaria in children is crucial to prevent malaria mortality and reduce 390 the overall global malaria burden¹. Through modelling and simulation, we explored a broad range of LAI 391 characteristics in multiple settings for clinical testing and deployment. This allowed us to understand the 392 likely influence of LAI efficacy properties and operational factors on clinical incidence reduction in 393 children under five years of age when LAI is deployed as a seasonal malaria prevention tool. We found that 394 if the protective efficacy of a new LAI decays immediately after injection, for example an exponential or 395 bi-phasic-like decay, then the LAI is unlikely to achieve non-inferiority over SMC-SP-AQ in current SMC 396 settings in a clinical trial. This exploration assumed non-inferiority criterion is required for testing, and we only explored LAI half-life of protection in the range of 30 to 150 days. In contrast, when the protective 397 398 efficacy of LAIs is long-lasting and decays only after some time (i.e. a sigmoidal decay), there is a stronger 399 chance of achieving non-inferiority when the duration of protection is close to the transmission length.

400 Beyond clinical stages, by assessing implementation factors versus LAI properties, we conclude that

401 focusing on enhancing the duration of protective efficacy (half-life) is more likely to result in successful

402 LAIs in a larger range of incidence and transmission settings. If the half-life of protective efficacy of a LAI

403 approaches the length of transmission season, and initial efficacy is sufficiently high (depending on the

transmission intensity (Fig. 2)), then the development of new LAI should prioritize optimizing operational

405 delivery factors to ensure reasonable coverage to be as good as or better in averting clinical cases than

406 current SMC-SP+AQ implementation.

407 The estimated impact of tool properties

408 In general, the duration of the half-life and its shape of decay are the most relevant tool properties for 409 incidence reduction. This means that the development of new LAIs should focus on understanding the likely

410 decay and half-life of protection (this is not the pharmacokinetic properties of a small molecule or the

411 antibody longevity of a mAb). Over the analyzed transmission settings and parameter space, the estimated

412 minimum essential (80%) and ideal (95%) incidence reduction targets for LAIs as defined by Macintyre et

413 al. $(2018)^{15}$ are hard to achieve in clinical testing. A desired incidence reduction of >80% in clinical testing

414 could only be achieved for LAIs with a sigmoidal decay shape and half-life over 60 days (Senegal, short

415 season) and 80 days (Mali, long season). Our findings indicate that key to identifying and refining

416 candidates for development of new LAIs is investigating the decay shape of efficacy as early as possible

417 and providing a sufficiently long protection half-life. Before conducting large scale clinical trials, it will

418 therefore be important to ensure the adequate means to establish the decay and duration of protection and 419 the ability to extrapolate to paediatric indications.

the ability to extrapolate to paediatric indications.

While the pharmacokinetic profile of potential LAIs can be evaluated in pharmacokinetic studies, their 420 protective efficacy profile and decay shape are harder to derive. Currently, murine ⁴⁶ or human challenge 421 ^{47,48} studies are being used to investigate these parameters. In these studies, subjects receive treatment before 422 423 inoculation with sporozoites through the bites of infectious mosquitoes or direct venous injection ^{47,48}. 424 However, parasite growth in the liver, and therefore protective efficacy, cannot be directly quantified. 425 Instead, the time and number of parasites entering the blood stream is used as a crude proxy for protective 426 efficacy. The approach presented here can aid to translate survival estimates from murine and human studies 427 by estimating the protective efficacy decay curves and then plugging them into the population modelling approach with OpenMalaria. Hence, our approach can provide first insights into the potential public health 428 impact of new LAIs. 429

In summary, our findings suggest that when defining key efficacy characteristics in TPPs for LAIs there are two important aspects to consider: i) evaluating the feasibility of currently or newly expect specified LAI efficacy and duration requirements ¹⁵ by estimating the likely public health impact of new LAIs with e.g. modeling and simulation approaches, and by ii) translating population efficacy on clinical cases into individual protection efficacy and vice versa via adequate summary measures of protective efficacy in

435 animal or human studies.

436 Clinical non-inferiority trials

437 Our non-inferiority analysis (Fig. 3) highlights that the establishment of non-inferiority in *clinical trial* 438 stages is challenging due to not only the high protective ability of SMC-SP+AQ but also clinical trial

439 designs. This motivates an important discussion on the clinical development of LAIs under the use-case of

440 SMC replacement: the necessity and extent of clinical trial testing or non-inferiority criteria should be 441 assessed. We estimated SMC-SP+AQ in a clinical study results in incidence reductions of 71% to 90% in children under five, aligning to a efficacy of 86% (95% CI 78–91%) in a clinical trial in Senegal⁴⁹. Monthly 442 443 SMC-SP+AQ administration together with the estimated protective efficacy half-life of 32 days offers a 444 high degree of protection and the blood-stage clearing effect of AQ eliminates remnant malaria infections, 445 making optimally employed SMC a very powerful tool to prevent clinical malaria. This means it is difficult 446 for most LAIs to achieve non-inferiority in a clinical trial with limited SP resistance when the LAI is only 447 deployed once per season in combination with a blood stage clearing drug. Thus, at first glance, our non-448 inferiority results may offer a distorted picture of the ability of LAIs to compete with current SMC, as clinical non-inferiority trials do not reflect the reality of SMC implementation. Operational constraints 449 result in reduced coverage over the number of rounds ^{5,6} and adherence ¹⁰, thus hindering SMC with SP+AQ 450 451 from reaching its full potential. AS SMC-SP+AQ effectiveness reduces with operational challenges, this 452 presents a niche for LAIs. In 2019 only 62% of eligible children received SMC-SP+AQ¹, meaning that 453 additional incidence reduction could be achieved by increasing coverage at each round.

454 **Tool and coverage optimization in implementation stages**

455 Replacing SMC-SP+AQ with LAIs will likely prove beneficial in reducing deployment costs due to fewer deployment rounds. In the absence of information on costs of LAIs (costs of goods and supply chain), we 456 457 are unable to adequately assess economic considerations and thus our results assume that coverage is the 458 main driver of implementation cost. If LAIs are assumed to have a longer clearance half-life and therefore 459 higher protective efficacy for longer than SP+AQ, resources are freed up through decreased deployment 460 rounds within a season. These resources could be reallocated to increase the overall coverage in a single 461 round of LAI in the target population, including populations in remote places. Additionally, the overall 462 adherence to the blood-stage clearing co-administration of antimalarials could be increased, thereby 463 reducing the probability of emergence of resistance. However, if transmission intensity is very high, we 464 found that the optimization of protective efficacy half-life and deployment coverage is insufficient to adequately protect the targeted population. Instead, it might be necessary to expand the deployment of LAIs 465 466 to multiple administration rounds within a transmission season.

The optimization of deployment coverage of LAIs to reach non-inferiority to SMC-SP+AQ where optimal coverage cannot be met exposes an additional use case for LAIs. If external circumstances, such as the current COVID-19 pandemic, prevent the regular implementation of SMC and bed-nets campaigns, millions of children will experience an increased risk of malaria ⁵⁰, LAIs may alleviate this burden. Our analysis can aid the identification of minimal LAI coverages necessary to achieve given population impacts

472 and prevent a resurgence in malaria cases.

473 Framework and areas of application

474 Our modelling and simulation analysis provides important insights into the likely impact of new malaria 475 tools that are currently under clinical development. Our modelling framework divides the unknown

476 parameter space of realistic properties of new tools into setting-specific attainable incidence reduction by

477 translating the decay of individual protection against infection of a new tool into estimates of population

- 478 impact on clinical incidence. While in clinical trials often only one (high) deployment coverage and a
- 479 limited number of trial-arms can be investigated, a simulation-based approach can explore the trade-off
- 480 between operational constraints and tool properties to narrow down beneficial implementation settings and

481 use cases without the need for expensive field studies. Not only does this approach offer the opportunity to 482 assess the potential population impact of new tools currently under development, but it also provides a 483 methodology to assess the potential clinical trial outcomes. It assists the evaluation of clinical trial scenarios 484 that might be considered over several different malaria transmission and health-system settings to 485 supporting thinking on appropriate population impact endpoints that are suitable to inform decision making. 486 This is particularly true for existing interventions with high efficacy for which the establishment of non-487 inferiority in clinical non -inferiority trials is problematic, due to the required large sample sizes ⁵¹. Here, 488 our approach offers first insights into the outcomes of such trials and the additional possibility to develop 489 clinical trial analysis tools.

Furthermore, beyond the current scope of our study, as more information on likely costs of LAIs become
 available and further certainty in implementation and cold-chain needed, this work can serve as a basis for
 cost-effectiveness or economic analysis.

493 As with all modelling studies there are limitations to our analysis. In this study, despite exploring a large 494 range of characteristics on tool properties, deployment, and transmission settings, our results are 495 constrained by the investigated parameter-space. First, we only investigated the impact of one 496 administration round of LAIs with an antimalarial treatment and assumed that the time-point of 497 administration would coincide with the first SMC application round. However, depending on the LAI 498 profile, the time of deployment may need to be optimized. Second, the implementation of protective 499 efficacy of LAIs is solely assumption-driven, as clinical data is not yet available. With additional 500 information on likely achievable protective efficacy half-life, initial protective efficacy and efficacy decay 501 shapes, the preliminary LAI profiles can be further defined and reevaluated as LAIs are developed. The redefinition of plausible parameter ranges will also impact the results of the sensitivity analysis and trade-502 503 offs, and potentially shift the recommended focus of development efforts. Additionally, target mediated 504 drug disposition might change the pharmacokinetic profile of mAbs dependent on the transmission intensity and parasite growth within the human host and therefore also its efficacy profile ⁵². Third, the focus of this 505 506 analysis was the investigation of the effect of the anti-infective LAIs. Our results are subject to change if 507 LAIs are co-administered with different blood-stage clearing drugs (different efficacies and/or potential 508 properties e.g. transmission blocking) or are deployed with other interventions such as insecticide-treated 509 bed-nets. And lastly, we explored SMC or LAI replacement in only children under 5 years of age and in 510 settings similar to where SMC is currently deployed such as Mali and Senegal. Further analysis could be 511 undertaken to assess LAI as seasonal prevention in children under 10 years of age, however we expect 512 conclusions to be similar in regards tool properties and coverage requirements. Our results also only hold 513 for assessing LAI as replacing SMC; we did not explore use cases of deploying LAI in perennial or other 514 settings in which SMC is not yet deployed. Alternative clinical metrics would need to be explored as LAI 515 in these use-cases are not a replacement tools, rather new tools and non-inferiority trials are not relevant. 516 Although this study focuses on the use of LAIs in seasonal malaria transmission settings, our findings 517 regarding the importance of protective efficacy half-life do provide first insights for potential use of a LAIs in perennial malaria transmission settings. The protective efficacy half-life of a LAI will most likely dictate 518 519 the number of applications to children within one year to ensure effective clinical case reduction.

520 Current stage of development of mABs and duration of protection

521 Potential candidate LAIs include mABs and small-molecule drugs, and to date most known mAbs for use in malaria (largely by-products from research into whole sporozoite vaccines ⁵³) have been shown to prevent 522 blood-stage infection in *in vitro* and/or *in vivo* murine malaria infection experiments ^{18,19}. As the natural 523 clearance half-life of antibodies ranges between 2 and 21 days ⁵⁴, strategies to increase the half-life of mAbs 524 have been introduced via modifications to the tail (Fc) region of antibodies that interacts with the receptors 525 on the surface of cells. Fc-modified mAbs have exhibited extended half-lifes ranging from, 100 days ⁵⁵ and 526 527 80 to 112 days ⁵⁶ in healthy human adults. Our results suggest that these extended half-lifes, if functional 528 malaria protection is maintained, are crucial to establish non-inferiority to standard SMC. A second stream 529 of LAI development is focused around small-molecule drugs such as atoyaquone ¹⁶ and P218¹⁷. Although these compounds show promising liver-stage activity, the estimated clearance half-life of enhanced 530 formulation atovaquone of 32 days in humans ¹⁶ and 8.9-19.6 hours of P218 in first-in-human trials ⁵⁷ are 531 532 again likely insufficient in the use cases explored in our study and emphasize the need for longer-lasting 533 formulations to be useful as SMC replacements when deployed only once per season. Further use may be 534 possible for multiple applications within a season.

535 Conclusion

Here, we provided the first quantitative evaluation of the TPPs of future LAIs for malaria as a seasonal 536 prevention tool in children. Simulation analysis of LAIs in real-life implementation settings revealed that 537 538 the ability of LAIs to prevent clinical cases in children is strongly dependent on the length of the malaria 539 transmission season and transmission intensity. We also found it is important to focus on improving the protective efficacy duration (half-life) of LAIs in development, as the speed of protective efficacy decay is 540 541 a key driver of overall impact or the chance to meet non-inferiority criteria compared to SMC-SP+AQ. However, if a reasonable duration is possible (longer half-life and sigmoidal decay that supports protection 542 543 close to the length of transmission season) then development should focus on increasing deployment coverage to optimizing the LAIs chance of higher impact. This provides evidence for the potential trade-544 545 offs between tool properties and operational constraints as LAIs are developed and deployed. In general, 546 our findings support the need for a thorough and combined investigation of tool properties and use cases in 547 the future development of LAIs. This combined effort includes earlier modelling alongside clinical studies 548 to provide evidence of translation of impact at population levels before late stage clinical studies and 549 optimize the success of new malaria tools. Our research here provides an initial foundation to support 550 dialogue between stakeholders, scientists, and clinicians at each clinical development stage of novel anti-551 infective LAI's to reduce clinical malaria incidence. LAIs have the potential to be a game changer in 552 protecting vulnerable populations from malaria. Our analysis serves as a stepping stone for the refinement 553 of TPPs for LAIs, thereby assisting the target-oriented use-case of development and implementation of new 554 LAIs.

555 List of abbreviations

SMC	Seasonal malaria chemoprevention
LAI	Long acting injectable
TPP	Target product profile
mAB	Monoclonal antibody
SP+AQ	Sulfadoxine-Pyrimethamine+Amodiaquine
GP	Gaussian process

556

557 **6. Declarations**

- 558 *Ethics approval and consent to participate*
- 559 Not applicable
- 560 Consent for publication
- 561 Not applicable

562 *Competing interests*

563 J.J.M. is employed by the Medicines for Malaria Venture. All other authors declare no competing interests.

564 Funding

565 The work was funded by the Swiss National Science Foundation through SNSF Professorship of MAP 566 (PP00P3 170702).

567 Authors' contributions

- 568 LB, ML, MP, and MG designed the simulation experiments and the computational framework. LB and ML
- 569 carried out the simulations, analysis and visualisation. LB, ML, MG, TR, JJM, and MP contributed to the
- 570 interpretation of the results. LB wrote the manuscript with input from ML, MG, TR, JJ, and MP. MP and
- 571 LB conceived the study and were in charge of overall direction and planning. MP supervised the project.
- 572 All authors read and approved the final manuscript.

573 Acknowledgments

- 574 We acknowledge and thank our colleagues in the Swiss TPH Infectious Disease Modeling unit for their
- 575 valuable insights and feedback. Calculations were performed at sciCORE (http://scicore.unibas.ch/)
- 576 scientific computing center at University of Basel.
- 577
- 578

579 Tables and Figures

580 Table 1: Summary of simulation set-up used for the implementation experiments. The simulated transmission settings were defined using a factorial design covering all possible combinations of discrete 581 582 health system and vector specifications. The parameters defining the efficacy and delivery profiles of LAIs 583 (highlighted in bold in the third column) were sampled within the defined parameter space using Latin 584 Hypercube Sampling and simulated for each combination of settings. The effective coverage E₁₄ describes the probability that effective malaria treatment will occur within a 14-day period since symptoms onset. 585 586 Additional information on simulated transmission intensity can be found in the Supplement (Fig. S1 and 587 Table S1).

	Parameter	Setting	Value						
	Access to treatment	High access	0.5						
Health	coverage ⁵⁸ E ₁₄)	Low access	0.3						
system	Diagnostics	-	Rapid dia	agnos	stic test				
U	Malaria treatment	-	First line	: AC	Γ				
			Treatment fai		lure/Sev	vere m	alaria:	Quini	ine
	EIR [infectious bites	High access	EIR		5	9	20	47	150
	per person per year]	Long season	cpppy _{0.25}	-5y	0.42	1	1.6	2.2	2.9
	and yearly cases per	Short season	cpppy _{0.25}	-5y	0.49	0.95	1.52	2.0	4 2.83
	person per year	Low access	EIR		3	4	8	28	150
	[cpppy _{0.25-5y}]	Long season	cpppy _{0.25}	-5y	0.41	0./1	1.4	2.4	3.3
Malaria	Mosquito species	Short season	An gamb	-5y hiae	0.43	0.72	1.5	2.3	5.2
transmission	Riting behavior	-	An. gumblue		door l	niting			
			Inl	Δ11σ	Ser		t ,	Nov	Dec
	Seasonality in malaria transmission	Senegal-like short season ⁵⁹	0	20	60	20		0	0
	[% yearly EIR]	Mali-like long season ⁶⁰	8	18	50	23		2	0
	Timing of	Senegal-short	t 3x SMC: Sep, Oct, and Nov						
	interventions	season Mali-long season	4x SMC: Aug, Sep, Oct, and Nov						
	Intervention cohort		3mo. – 5	years	S				
	Population treated		Coverage: [40 - 100] %						
	Protective efficacy LAI		Initial efficacy: [70 - 100] % Half-life: [30-150] days						
Interventions			Decay sh	ape:					
		exponential LAIs bi-phasic LAIs sigmoidal LAIs	Exponential decay, k=1 (Eq. 1) Bi-phasic decay, k=0.69 (Eq. 1) Sigmoidal decay, k= 8 (Eq. 2)						
	Protective efficacy		Initial eff	ficacy	y: 100 9	%	<i>*</i>		
	SMC-SP+AQ		Half-life:	: 32 d	lays				
			Decay sh	ape:	Weibu	ll, k= 5	.4 (Eq	j . 1)	
			Adherend	ce de	clining	by 10%	6 ove	r the se	eason

589 Table 2: Illustration of the trade-offs between LAI protective efficacy half-life, initial protective 590 efficacy and coverage in *implementation stages*. The table displays the estimated minimum half-life of 591 LAI protective efficacy (measured in days, estimated values specified in the colored cells, increasing colour 592 intensity illustrates increasing requirements) required to reach non-inferiority in implementation stages of 593 various LAI profiles compared to SMC-SP+AO deployed at 60% coverage for each of 3 or 4 rounds in a 594 setting with low access to health care ($E_{14} = 0.1$). SMC-SP-AQ protective efficacy specifications are 595 summarized in Table 1. Results are shown for different levels of LAI coverage, decay shapes (exponential 596 or sigmoidal), initial protective efficacy and malaria incidence prior to deployment (initial cases per person 597 per year_{0.25-5v}).

	<i>Exponential LAIs</i> Coverage [%]		5		<i>Sigmoid</i> Covera	<i>lal LAIs</i> age [%]	<i>al LAIs</i> ge [%]		
Efficacy [%]	initial cases per person per year _{0.25-5y}	40%	60%	80%	100%	40%	60%	80%	100%
	0.41	-	-	113	62	-	-	85	59
700/	0.71	-	-		70	-	-	87	63
/0%	1.4	-	-	-	89	-	-	103	63
	2.4	-	-	-	93	-	-	105	79
	3.3	-	-	-	-	-	-	-	-
	0.41	-	-	109	54	-	-	71	52
0.00/	0.71	-	-	112	62	-	148	74	55
80%	1.4	-	-	132	64	-	-	77	57
	2.4	-	-	119	75	-	-	84	62
	3.3	-	-	-	-	-	-	-	-
	0.41	-	-	81	48	-	102	61	50
0.00/	0.71	-	-	79	52	-	86	64	52
90%	1.4	-	-	90	56	-	103	63	49
	2.4	-	-	92	62	-	97	72	56
	3.3	-	-	-	-	-	-	-	-
	0.41	-	112	62	46	-	78	58	47
1000/	0.71	-	115	69	48	-	78	58	49
10070	1.4	-	131	71	49	-	78	58	47
	2.4	-	119	72	52	-	80	61	47
	3.3	-	-	-	-	-	-	-	-

598



601 Figure 1: Workflow to assess the target product profile of LAIs. (a) In an iterative exchange between 602 various stakeholders, definition of TPPs is informed by results from modelling approaches. Simulation of predefined scenarios with OpenMalaria, an individual based model of malaria dynamics, allows to estimate 603 the impact (incidence reduction) of LAIs in the context of deployment setting details (access to healthcare 604 605 and seasonality), deployment coverage of the target population and the tool properties (initial protective 606 efficacy against infection, protective efficacy half-life and decay of protective efficacy). The resulting 607 evaluation of LAI impact is communicated and discussed with stakeholders to refine the analysis as LAIs 608 are developed. (b) The analysis in the clinical trial and implementation stage are illustrated on the example of two hypothetical LAIs with different efficacy profiles (denoted LAI 1 and 2). (1) In clinical trial stages, 609 610 the minimum essential properties to reach a certain health goal are evaluated in a two-arm clinical trial. 611 SMC-SP+AQ is administered (green arrows) three (as in Senegal, filled arrows) or four (as in Mali, filled and unfilled arrows) times over the transmission season. LAIs are administered once at the beginning of 612 613 the transmission season (blue filled arrow for Senegal and blue empty arrow for Mali). The cumulative cases per person over the trial period are tracked. (2) In implementation stages, SMC-SP+AQ is replaced 614 with LAIs after five years of implementation. Impact is assessed in the last implementation year (grey bar) 615 and compared to the baseline of SMC-SP+AQ implementation. Coverages of SMC-SP+AQ and LAIs are 616 independent from each other. (3) Upper panel: the tool properties influencing the establishment of non-617 618 inferiority of LAIs to SMC are investigated in the clinical trial stage. Lower panel: at a fixed SMC deployment coverage, the minimum coverage of LAI deployment required to establish non-inferiority is 619 620 identified.

621



622

623 Figure 2: Achieving targeted malaria incidence reduction depends on the decay shape of the LAIs 624 protective efficacy. Estimated relationships between initial protective efficacy and efficacy half-life for different incidence reduction criteria (40%, 60% and 80%, line style and color) and clinical incidence 625 626 settings (increasing color intensity indicates an initial clinical incidence measured in cases per person per 627 year in the target age group of 0.5, 1, 1.5, 2, and 2.8). Each line shows the minimum required LAI 628 characteristics to reach the desired health goal at a 100% LAI deployment coverage at *clinical trial stage*, 629 with all parameter combinations below a line failing to meet those requirements. The panels show the 630 parameter space of attainable incidence reductions within the specified constrained ranges of initial 631 protective efficacy and half-life for exponential LAIs (a, b), bi-phasic LAIs (c, d) and sigmoidal LAIs (e, f) 632 in settings with a short (Senegal-like a, c, e) or long (Mali-like b, d, f) malaria season. The incidence 633 reduction was calculated by comparing the incidence over one transmission season after application of the

LAI compared to the previous transmission season. The incidence reductions were obtained by predicting the cases per person per year_{0.25-5y} via our emulator approach (See Methods and Supplementary Information) in a fine grid defined over the parameter space (increments of 0.1 h for half-life and 0.01% for initial protective efficacy) and calculating the incidence reduction by comparison to the initial clinical incidence measured in cases per person per year_{0.25-5y} in the respective transmission intensity setting.



Figure 3: Parameter space under which sigmoidal LAIs achieve non-inferiority compared to SMC-640 641 SP+AQ in the clinical trial stage. We investigated the ability of sigmoidal LAIs to establish non-inferiority in clinical trials with an optimal deployment coverage (100%) in settings with a short (a, c) and long (b, d) 642 643 malaria season and over varying initial malaria incidence (initial cases per person per year $_{0.25-5v}$). (a, b) 644 SMC-SP+AQ has an initial protective efficacy of 100% and a half-life of 32 days parameterised from previous clinical trial data¹. The influence of prevalent SP-resistance (c, d) was analyzed by decreasing the 645 protective efficacy half-life of SP from 32 days to 20 days (see Supplementary Information). The coloured 646 647 area defines the limits of the parameter space where non-inferiority could be established through 648 comparison of the difference hazard ratio δ between Kaplan-Meier survival estimates (see Supplementary 649 information). The white area describes the parameter space where LAIs are inferior. Sigmoidal LAIs can 650 achieve non-inferiority compared to SMC for lower durations of protection in a shorter malaria transmission 651 season. Exponential LAIs and bi-phasic LAIs could not establish non-inferiority to SMC-SP+AQ.



653

long season; sigmoidal LAIs

654 Figure 4: Estimated importance of LAI properties and operational factors on the level of clinical 655 incidence reduction. Results are shown for the *implementation stage* for *sigmoidal LAIs* in a setting with low access to care and long malaria transmission season. (a, b) Sobol sensitivity analysis estimates the 656 657 relative importance of LAI coverage, initial protective efficacy and half-life of protective efficacy to the 658 variance of the emulator through decomposition of variance over the entire evaluated parameter space 659 (coverage 40-100%, initial efficacy 70-100% and half-life (a) 30-90 days and (b) 90-150 days). Changes in clinical incidence measured as cases per person per year_{0.25-5y} with increasing tool properties or 660 661 deployment coverage across the parameter space are shown for (c) half-life (30-150 days), (d) initial efficacy (80-100%) and (e) coverage (40 -100%). The lines represent the mean and the 95%- confidence 662 663 bands (shaded area) capture the distribution of incidence reduction across all sampled values. The dotted line in panel c indicates the split of half-life range for sensitivity analysis in panel a and b. Increasing color 664 intensity represents increasing initial cases per person per year_{0.25-5y}. Further results for different decay 665 shapes and length of transmission season are shown in the Supplementary Figures S4 and S5. 666



667

668 Figure 5: Estimated minimal LAI coverage required during *implementation stages* to achieve noninferiority in a given setting and predicted gains in cases averted of subsequent sigmoidal LAI 669 670 coverage increments. (a) Heatmap of the estimated minimal coverage (colour) of sigmoidal LAIs at which 671 non-inferiority to SMC-SP+AQ (assuming a fixed SMC coverage of 60%) is achieved for different 672 combinations of sigmoidal LAI efficacy and half-life. The results are displayed for intervention scenarios 673 with an underlying disease burden of 1.4 cases per person per year_{0.25-5y}, long malaria transmission season 674 and low access to treatment ($E_{14}=0.1$). In the grey area, non-inferiority of LAIs could not be established for 675 any coverage. The light blue frames capture the tool characteristics where non-inferiority could be reached 676 with a LAI coverage under the reference SMC-SP+AQ coverage of 60%. Further results for additional settings and decay shapes are provided in the supplement (Fig. S8 and S9). The coloured dots represent 677 four illustrative LAI profiles for which the corresponding predicted relative differences in cases per person 678 679 per year_{0.25-5y} (Eq. 5) are calculated in (b-e) five years after LAI introduction over all LAI coverages as 680 compared to SMC-SP+AQ at 60% coverage (vertical dotted line). The predicted positive increase in relative 681 difference in yearly clinical cases (above the dotted horizontal line) means more clinical cases are averted 682 with LAIs than with SMC-SP+AO. It thus illustrates the benefit of increasing sigmoidal LAI-coverage 683 above the minimal required coverage to achieve non-inferiority (shown by the grey coloured area). Due to the chosen margin of non-inferiority (here 5%, see Material and Methods), LAIs are non-inferior for a slight 684 negative relative difference in cases per person per year_{0.25-5y}. In the light-blue area in (b), a LAI coverage 685 686 lower than the SMC-SP+AQ coverage is sufficient to establish non-inferiority. The corresponding analysis 687 for exponential LAIs can be found in Fig. S10.

689

690 1. WHO. World malaria report 2019. (World Health Organization, 2019).

Bhatt, S. *et al.* The effect of malaria control on Plasmodium falciparum in Africa between 2000
and 2015. *Nature* 526, 207–211 (9).

WHO. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium
 falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. (World
 Health Organization, 2012).

4. Zongo, I. *et al.* Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared
with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina
Faso. *Antimicrob. Agents Chemother.* 59, 4387–4396 (2015).

699 5. Cisse, B. *et al.* Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years
700 of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. *PLoS Med* 13, e1002175 (2016).

701 6. Druetz, T. Evaluation of direct and indirect effects of seasonal malaria chemoprevention in Mali.
 702 Sci. Rep. 8, 8104 (2018).

703 7. Coldiron, M. E., Von Seidlein, L. & Grais, R. F. Seasonal malaria chemoprevention: successes and
 704 missed opportunities. *Malar. J.* 16, 481 (2017).

8. Loua, K. & Milligan, P. Seasonal Malaria Chemoprevention Coverage Survey in Guinea, 2018.
(2019).

Diawara, F. *et al.* Measuring the impact of seasonal malaria chemoprevention as part of routine
malaria control in Kita, Mali. *Malar. J.* 16, 325 (2017).

10. Ding, J. *et al.* Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used
for Seasonal Malaria Chemoprevention in African Children. *Clin Pharmacol Ther* (2019)
doi:10.1002/cpt.1707.

11. Somé, A. F. *et al.* Selection of drug resistance-mediating Plasmodium falciparum genetic
polymorphisms by seasonal malaria chemoprevention in Burkina Faso. *Antimicrob. Agents Chemother.* 58,
3660–3665 (2014).

Dieng *et al.* Contrasting Asymptomatic and Drug Resistance Gene Prevalence of Plasmodium
 falciparum in Ghana: Implications on Seasonal Malaria Chemoprevention. *Genes* 10, 538 (2019).

van Lenthe, M. *et al.* Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic
Republic of Congo; implications for malaria chemoprevention. *Malar. J.* 18, 430 (2019).

719 14. WHO. Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in
720 children: A field guide. (World Health Organization, 2013).

15. Macintyre, F. *et al.* Injectable anti-malarials revisited: discovery and development of new agents
to protect against malaria. *Malar. J.* 17, 402–402 (2018).

Bakshi, R. P. *et al.* Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. *Nat. Commun.* 9, 315 (2018).

- Yuthavong, Y. *et al.* Malarial dihydrofolate reductase as a paradigm for drug development against
 a resistance-compromised target. *Proc. Natl. Acad. Sci. U. S. A.* 109, 16823–16828 (2012).
- 18. Kisalu, N. K. *et al.* A human monoclonal antibody prevents malaria infection by targeting a new
 site of vulnerability on the parasite. *Nat Med* 24, 408–416 (2018).
- Tan, J. *et al.* A public antibody lineage that potently inhibits malaria infection by dual binding to
 the circumsporozoite protein. *Nat. Med.* 24, 401–407 (2018).
- 731 20. Golumbeanu, M. *et al.* A quantitative approach to guide development of novel disease 732 interventions, submitted. (2020).
- Maire, N. *et al.* A model for natural immunity to asexual blood stages of Plasmodium falciparum
 malaria in endemic areas. *Am. J. Trop. Med. Hyg.* **75**, 19–31 (2006).

Penny, M. A. *et al.* Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine:
a systematic comparison of predictions from four mathematical models. *Lancet Lond. Engl.* 387, 367–375
(2016).

- Chitnis, N., Hardy, D. & Smith, T. A periodically-forced mathematical model for the seasonal
 dynamics of malaria in mosquitoes. *Bull. Math. Biol.* 74, 1098–1124 (2012).
- Chitnis, N., Smith, T. & Steketee, R. A mathematical model for the dynamics of malaria in
 mosquitoes feeding on a heterogeneous host population. *J. Biol. Dyn.* 2, 259–285 (2008).
- 742 25. Smith, T. *et al.* An epidemiological model of the incidence of acute illness in Plasmodium
 743 falciparum malaria. *Am. J. Trop. Med. Hyg.* **75**, 56–62 (2006).
- Ross, A., Killeen, G. & Smith, T. Relationships between host infectivity to mosquitoes and asexual
 parasite density in Plasmodium falciparum. *Am. J. Trop. Med. Hyg.* **75**, 32–37 (2006).
- 746 27. Reiker, T., Chitnis, N. & Smith, T. Modelling reactive case detection strategies for interrupting
 747 transmission of Plasmodium falciparum malaria. *Malar. J.* 18, 259 (2019).
- Cameron, E. *et al.* Defining the relationship between infection prevalence and clinical incidence of
 Plasmodium falciparum malaria. *Nat. Commun.* 6, 8170 (2015).
- Bâ, E.-H. *et al.* Implementation, coverage and equity of large-scale door-to-door delivery of
 Seasonal Malaria Chemoprevention (SMC) to children under 10 in Senegal. *Sci. Rep.* 8, 1–15 (2018).
- 752 30. Ekström, A. M. *et al.* INDEPTH Network: contributing to the data revolution. *Lancet Diabetes*753 *Endocrinol.* 4, 97 (2016).
- Tediosi, F. *et al.* An approach to model the costs and effects of case management of Plasmodium
 falciparum malaria in sub-saharan Africa. *Am. J. Trop. Med. Hyg.* **75**, 90–103 (2006).

- 756 32. WHO. Country profiles. https://www.who.int/malaria/publications/country-profiles/en/ (2020).
- 757 33. Stein, M. Large Sample Properties of Simulations Using Latin Hypercube Sampling.
 758 *Technometrics* 29, 143–151 (1987).
- 759 34. OpenMalaria github. https://github.com/SwissTPH/openmalaria/.
- 35. White, M. T. *et al.* Dynamics of the antibody response to Plasmodium falciparum infection in
 African children. *J. Infect. Dis.* 210, 1115–1122 (2014).
- 762 36. Penny, M. A., Pemberton-Ross, P. & Smith, T. A. The time-course of protection of the RTS,S
 763 vaccine against malaria infections and clinical disease. *Malar. J.* 14, 437 (2015).
- 37. Griffin, J. T. *et al.* Protective Efficacy of Intermittent Preventive Treatment of Malaria in Infants
 (IPTi) Using Sulfadoxine-Pyrimethamine and Parasite Resistance. *PLOS ONE* 5, e12618 (2010).
- Aponte, J. J. *et al.* Efficacy and safety of intermittent preventive treatment with sulfadoxine pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
 The Lancet 374, 1533–1542 (2009).
- Rasmussen, C. E. Gaussian Processes in Machine Learning. in Advanced Lectures on Machine *Learning: ML Summer Schools 2003, Canberra, Australia, February 2 14, 2003, Tübingen, Germany, August 4 16, 2003, Revised Lectures* (eds. Bousquet, O., von Luxburg, U. & Rätsch, G.) 63–71 (Springer
 Berlin Heidelberg, 2004). doi:10.1007/978-3-540-28650-9 4.
- 40. Kock, M. de *et al.* Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a
 Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. *Antimicrob. Agents Chemother.* 62, (2018).
- 41. Dahal, P. *et al.* Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated
 Plasmodium falciparum malaria: pitfalls and challenges. *Malar. J.* 16, 430–430 (2017).
- 42. Binois, M. & Gramacy, R. B. hetGP: Heteroskedastic Gaussian Process Modeling and Design
 under Replication. *R package version* (2017).
- 43. Sobol', I. M. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo
 estimates. *Math. Comput. Simul.* 55, 271–280 (2001).
- Pitt, C. *et al.* Large-scale delivery of seasonal malaria chemoprevention to children under 10 in
 Senegal: an economic analysis. *Health Policy Plan.* 32, 1256–1266 (2017).
- Gilmartin, C. & Collins, D. *The Costs of Seasonal Malaria Chemoprevention (SMC) in the Sahel Sub-Region of Africa: A Multi-Country Cost Analysis of the ACCESS-SMC project.* (2016).
- Flannery, E. L. *et al.* Assessing drug efficacy against Plasmodium falciparum liver stages in vivo. *JCI Insight* 3,.
- 788 47. NCT03707041. Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge
 789 Model. https://clinicaltrials.gov/ct2/show/record/NCT03707041 (2019).

48. Sulyok, M. *et al.* DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double
blinded, phase 1 trial with controlled human malaria infection. *Lancet Infect. Dis.* 17, 636–644 (2017).

49. Cissé, B. *et al.* Seasonal intermittent preventive treatment with artesunate and sulfadoxinepyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, doubleblind trial. *Lancet Lond. Engl.* 367, 659–667 (2006).

795 50. Rogerson, S. J. *et al.* Identifying and combating the impacts of COVID-19 on malaria. *BMC Med.*796 18, 239 (2020).

51. Borrmann, S., Peto, T., Snow, R. W., Gutteridge, W. & White, N. J. Revisiting the design of phase
III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. *PLoS Med.* 5,
e227–e227 (2008).

Kamath, A. V. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. *Drug Discov. Today Technol.* 21–22, 75–83 (2016).

53. Julien, J.-P. & Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular
level. *Nat. Rev. Immunol.* 19, 761–775 (2019).

- Kontermann, R. E. Strategies to extend plasma half-lives of recombinant antibodies. *BioDrugs Clin. Immunother. Biopharm. Gene Ther.* 23, 93–109 (2009).
- 806 55. Robbie, G. J. *et al.* A Novel Investigational Fc-Modified Humanized Monoclonal Antibody,
 807 Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults. *Antimicrob. Agents Chemother.* 57,
 808 6147–6153 (2013).
- S6. Yu, X.-Q. *et al.* Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational,
 Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy
 Adults. *Antimicrob. Agents Chemother.* 61, (2017).
- S7. Chughlay, M. F. *et al.* First-in-human clinical trial to assess the safety, tolerability and
 pharmacokinetics of P218, a novel candidate for malaria chemoprotection. *Br. J. Clin. Pharmacol.* 86,
 1113–1124 (2020).
- 815 58. Penny, M. A. *et al.* Distribution of malaria exposure in endemic countries in Africa considering
 816 country levels of effective treatment. *Malar. J.* 14, 384 (2015).

59. Diouf, I. *et al.* Détermination des paramètres du paludisme au Sénégal à partir de données
météorlogiques de stations et de réanalyses. *XXVIIIe Colloque de l'Association Internationale de Climatologie, Liège 2015* (2015).

- 820 60. Traore, M. M. *et al.* Large-scale field trial of attractive toxic sugar baits (ATSB) for the control of
 821 malaria vector mosquitoes in Mali, West Africa. *Malar. J.* 19, 72 (2020).
- 822
- 823

824	Supplementary material for
825	Model informed target product profiles of long acting injectables for use as
826	seasonal malaria prevention
827	
828	
829	Authors:
830	Lydia Burgert ^{1, 2} , Theresa Reiker ^{1, 2} , Monica Golumbeanu ^{1,2} , Jörg J. Möhrle ^{1, 2, 3} , Melissa A. Penny* ^{1, 2}
831	¹ Swiss Tropical and Public Health Institute, Basel, Switzerland
832	² University of Basel, Basel, Switzerland
833	³ Medicines for Malaria Venture, Geneva, Switzerland
834	*Corresponding author: melissa.penny@unibas.ch
835	

836 Table of Contents

837	1.	General Open Malaria specification and intervention set-up
838	2.	Non-inferiority analysis
839	3.	Additional analysis results Error! Bookmark not defined.
840	4.	Additional analysis results in the clinical trial setting35
841	5.	Additional analysis results in the implementation setting
842 843	6.	Parameterization of SMC-SP+AQ to clinical trial data43



845 **1. General OpenMalaria specification and intervention set-up**

Figure S 1: Prevalence - incidence relationship in the simulated Open Malaria settings. The relationship between prevalence and incidence is displayed in the two simulated seasonal settings (Senegal/short season and Mali/long season) and health system access settings (low and high access) (Table 1) in absence of any interventions. The clinical incidence defined as the events per person per year in the target age-group (0.25-5 years of age) is shown for the corresponding mean prevalence over one year in the intervention age group (*Pf*PR_{0.25-5y}) and in children between 2-10 years (*Pf*PR_{2-10y}). The dotted horizontal lines mark the incidence settings, simulated for all downstream analyses and can be found in Table S1.

Table S 1: Simulated prevalence – incidence settings. The force of transmission was defined by the entomological inoculation rate (EIR: mean number of infectious bites per person per year (pppy)). Across different transmission settings defined by health system access, EIR levels and transmission seasonality, corresponding simulated malaria prevalence (PfPR) and clinical incidence per person per year in the intervention age group is displayed for different age groups: 2 to 10 year olds (PfPR_{2-10y}) and 0.25 to 5 years old (PfPR_{0.25-5y} and cases per person per year_{0.25-5y}).

		Short transmission season			Long	transmission s	season
HS Access	EIR [infectious bites pppy]	PfPR 2-10y [%]	PfPR 0.25-5y [%]	Cases per person per year _{0.25-5y}	PfPR 2-10y [%]	PfPR 0.25-5y [%]	Cases per person per year _{0.25-5y}
	5	6	5	0.49	6	5	0.42
_	9	13	11	0.95	13	10	1
high	20	23	19	1.52	25	20	1.6
	47	37	28	2.04	39	30	2.2
	150	60	45	2.83	62	46	2.9
	3	11	8	0.45	11	8	0.41
	4	19	13	0.72	17	13	0.71
0 M	8	34	26	1.3	35	26	1.4
, ,	28	59	48	2.3	62	50	2.4
	150	86	73	3.2	87	75	3.3







867

Figure S 3: Simulated protective efficacy decay shapes of long acting injectables (LAI) and seasonal malaria chemoprevention (SMC) over one transmission season. The LAI decay shapes were chosen such that they represent the three possible development streams of mAb (sigmoid decay), drug based (exponential decay), or vaccine like (bi-phasic) LAIs (blue solid line). Here, we illustrated a LAI protective efficacy half-life of 120 days and initial protective efficacy of 100 %. SMC – SP+AQ was parameterised as specified below and administered up to four times over the transmission season (green solid line). The parameterisation of the interventions is further specified in Table 1.



876 Figure S 4: Exemplary illustration of incidence and survival estimates of sigmoidal LAIs and SMC-SP+AQ in *implementation stages* over one implementation year. Plots are shown in (a, c) low initial 877 clinical incidence settings (initial cases per person per year_{0.25-5y} = 0.71) and (b, d) high initial clinical 878 incidence settings (initial cases per person per year_{0.25-5y} = 3.3) in long malaria transmission settings with 879 low access to health care (E14=0.1). The sigmoidal LAIs exhibit an initial protective efficacy over 95 % and 880 protective efficacy half-life of 112 days. SMC-SP+AQ and LAIs were implemented at high deployment 881 882 coverage (>90%, solid lines) and low deployment coverage (<50%, dashed lines). In low initial incidence 883 settings (a, c) SMC-SP+AQ (green) is administered four times per season (Aug-Nov) with clinical 884 incidence notably decreasing after each administration (a, b) compared to control settings with no 885 implemented interventions (black). In contrast, the sigmoidal LAIs are only administered once at the 886 beginning of the transmission season. With progressing season, the protective efficacy decays, resulting in 887 an increase of clinical cases (a, b) and decrease in survival estimates (c, d) after LAI administration. In low 888 clinical incidence settings, sigmoidal LAIs and SMC-SP+AQ are comparably effective at both coverage levels (c). In contrast, the survival estimates in in high initial clinical incidence settings (d) reveal that 889 890 sigmoidal LAIs at both coverage levels and SMC-SP+AQ at low coverage levels are all equally unable to 891 prevent malaria cases. Shown here are the mean predictions over 5 stochastic OpenMalaria simulations.

892

893 **2. Non-inferiority analysis**

894

897 898

895 Survival analysis was performed using a Kaplan-Meier approach as specified in ², with the K-M estimate 896 $\hat{S}(t)$ derived via number of new clinical cases c_i at each time step t_i

$$\widehat{S}(t) = \prod_{i:t_i \le t} 1 - \frac{c_i}{N_{int}},$$
 Equ. S6

899 with the standard error \widehat{SE} calculated using the Greenwood formula

900
$$\widehat{SE}(t) = \left[\widehat{S}(t)\right] \sqrt{\prod_{i:t_i \le t} \frac{c_i}{N_{int}(N_{int} - c_i)}}.$$
 Eq. S7

901 Non-inferiority analysis was conducted based on the survival statistics as described in ². The survival 902 estimate (hazard ratio) for the standard of care SMC \hat{S}_{SMC} (t) considering the desired margin of non-903 inferiority Δ defines the upper limit for non-inferiority γ :

904
$$\gamma = \frac{\ln (\hat{s}_{SMC} - \Delta)}{\ln (\hat{s}_{SMC})}$$
 Eq. S8

905 The difference δ between the survival estimates of the standard of care SMC \hat{S}_{SMC} (t) and new treatment 906 (LAI) \hat{S}_{LAI} , is calculated on the log-log- scale and is equivalent to the logarithm of the ratio of cumulative 907 hazards in the two groups

908
$$\delta = \ln\left(-\ln\left(\hat{S}_{SMC}\right)\right) - \ln\left(-\ln\left(\hat{S}_{LAI}\right)\right) = \ln\frac{\hat{H}_{SMC}(t)}{\hat{H}_{LAI}(t)}$$

909

910 and its variance is calculated as follows:

911
$$Var(\delta) = \left\{\frac{1}{\ln(\hat{s}_{SMC})}\right\}^2 \frac{1}{\hat{s}_{SMC}} Var(\hat{s}_{SMC}) + \left\{\frac{1}{\ln(\hat{s}_{LAI})}\right\}^2 \frac{1}{\hat{s}_{LAI}} Var(\hat{s}_{LAI}) \text{ Eq. S10}$$

912 The confidence interval of the hazard ratio δ is given by $exp^{\delta [95\% CI: \delta \pm 1.96 \times se(\delta)]}$. Non-inferiority is

913 established if the upper limit of the derived 95% confidence interval, CI_{high} , of the hazard ratios δ between

914 SMC and LAI lies below the upper limit for non-inferiority γ .

915

Eq. **S9**

916 **3. Emulator performance**

Table S 2: Emulator performance for the investigated outcomes. The emulator performance was
assessed by calculating the Pearson correlation coefficient (PCC) and the mean absolute error (MAE)
between true and predicted values on a 20% holdout set for each investigated setting.

Outcomo	РСС	MAE		
Outcome	(median [min, max])	(median [min, max])		
upper limit for non-inferiority γ	0.9924 [0.8072, 0.9972]	0.0015 [0.0002, 0.0280]		
upper limit of the hazard ratio	0.9945 [0.9472, 0.9978]	0.0229 [0.0094, 0.0791]		
Clinical incidence SMC-SP+AQ,	0.9964 [0.9787, 0.9986]	0.0142 [0.0060, 0.0428]		
(cases per person per year _{0.25-5y, SMC})				
Clinical incidence LAIs,	0.9947 [0.9562, 0.9985]	0.0136 [0.0055, 0.0488]		
(cases per person per year _{0.25-5y, LAI})				

920

921 **4.** Additional analysis results in the clinical trial setting

922 Table S 3: Incidence reduction achieved through implementation of SMC-SP+AQ in a clinical trial

923 setting. The incidence reduction was calculated in the clinical trial setting over three months in the short 924 season setting and four months in the long season setting. Resistance to SMC-SP+AQ is implemented as a

925 reduction in protective efficacy half-life from 32 days to 20 days.

		Short malaria transmission season	long malaria transmission season
	EIR [infectious bites pppy]	inc _{red} [%]	inc _{red} [%]
e	5	90	87
Q C Iano	9	90	87
sist SM P+A	20	90	88
SI to re	47	89	87
Z	150	88	86
0 0	3	79	76
ce t +A(4	76	75
esistan MC-SP	8	76	72
	28	73	72
a is	150	73	71

927 5. Additional analysis results in the implementation setting









941 Figure S 6: Estimated impact of LAI properties and operational factors on the level of clinical 942 incidence reduction. Results are shown for the implementation stage in a setting with low access to care 943 (E₁₄=0.1) and long (Mali-like) malaria transmission season, for (a-c) exponential LAIs, (d-f) bi-phasic LAIs, 944 and (g-i) sigmoidal LAIs. Changes in clinical incidence measured as cases per person per year_{0.25-5y} with 945 increasing tool properties or deployment coverage across the parameter space are shown for for (a, d, g) 946 half-life (30-150 d), (b, e, h) initial efficacy (80-100%) and (c, f, i) coverage (40 -100 %). The lines 947 represent the mean and the 95%- confidence bands (shaded area) capture the distribution of incidence 948 reduction across all sampled values. Increasing color intensity represents increasing initial clinical 949 incidence (cases per person per year_{0.25-5y}). These results hold true for high access to healthcare settings. 950 The conversion of initial cases per person per year_{0.25-5y} to prevalence can be found in Table S1.

951



952

Figure S 7: Incidence reduction achieved through implementation of SMC-SP+AQ over varying deployment coverage. The results are shown for low (a, b) and high (c, d) access to health care and short (a, c) and long (b, d) malaria seasons. The colors indicate different initial clinical incidence before introduction of SMC-SP+AQ (initial cases per person per year_{0.25-5y}). The incidence reduction_{0.25-5y} was calculated in the implementation scenario after one year of implementation. The grey lines indicate the additional incidence reduction _{0.25-5y}) achieved by increasing SMC-SP+AQ coverage from 62% to 100 %.



961 Figure S 8: Estimated minimal LAI coverage required during implementation stages to achieve non-962 inferiority in a given setting. Heatmap of the estimated minimal coverage (colour) of LAIs at which non-963 inferiority to SMC-SP+AQ (assuming a fixed SMC coverage of 60% in each of the 3 or 4 rounds) is 964 achieved for different combinations of protective efficacy decay, initial protective efficacy and protective efficacy half-life. The results are displayed for intervention scenarios with a low access to care ($E_{14}=0.1$) in 965 966 the two seasonal settings. In the grey area, non-inferiority could not be established for any combination of 967 tool properties. The LAI coverage could not be optimized for high transmission settings (initial cases per 968 person per year_{0.25-5y}=3.2) because they fail to sufficiently protect the targeted population from clinical 969 malaria even at full deployment coverage. Therefore, optimisation of the LAI deployment coverage could 970 not be conducted (Fig. S4).





980 malaria even at full deployment coverage. Therefore, optimisation of the LAI deployment coverage could

981 not be conducted (Fig. S4).



982

983 Figure S10: Estimated minimal LAI coverage required during implementation stages to achieve non-984 inferiority in a given setting and predicted gains in cases averted of subsequent exponential LAI 985 coverage increments. ((a) Heatmap of the estimated minimal coverage (colour) of sigmoidal LAIs at which 986 non-inferiority to SMC-SP+AQ (assuming a fixed SMC coverage of 60%) is achieved for different 987 combinations of exponential LAI efficacy and half-life. The results are displayed for intervention scenarios 988 with an underlying disease burden of 1.4 cases per person per year_{0.25-5y}, long malaria transmission season 989 and low access to treatment ($E_{14}=0.1$). In the grey area, non-inferiority could not be established for any 990 coverage. For the tool characteristics within the light-blue frames, non-inferiority could be reached with a 991 LAI coverage under the reference SMC-SP+AQ coverage of 60%. The coloured dots represent four 992 illustrative LAI profiles of (b)150 days half-life and 100% initial efficacy (yellow), (c) 100 days half-life 993 and 90% initial efficacy (light green), (d) 90 days half-life and 80% initial efficacy (blue), and (e) 70 days 994 half-life and 70% initial efficacy (dark green, e). (b-e). Corresponding predicted relative differences in 995 cases per person per year_{0.25-5y} (Eq. 5) are calculated for the illustrative LAIs (coloured dots) in (a) in the 996 last implementation year (5 years after LAI introduction) over all LAI coverages as compared to SMC-997 SP+AQ at 60% coverage (vertical dotted line). The predicted positive increase in relative difference in 998 yearly clinical cases (above the dotted horizontal line) means more clinical cases are averted with LAIs 999 than with SMC-SP+AQ. It thus illustrates the benefit of increasing exponential LAI-coverage above the minimal required coverage to achieve non-inferiority (shown by the grey coloured area). In the light-blue 1000 1001 area in (b), a LAI coverage lower than the SMC-SP+AO coverage is sufficient to establish non-inferiority.

1002

1004 6. Parameterization of SMC-SP+AQ to clinical trial data

1005 Seasonal malaria chemoprotection (SMC) was implemented as sulfadoxine–pyrimethamine+amodiquine 1006 (SP-AQ) treatment and calibrated to a randomized non-inferiority trial of dihydroartemisinin-piperaquine 1007 with SP-AQ, conducted between August 2009 and January 2010 in rural western Burkina Faso Zongo et 1008 $al.(2015)^3$. Decay of protective efficacy of SPAQ in the field over time was extracted from Fig.3 in Zongo 1009 et $al.(2015)^3$ and used to parameterized the decay functions as specified in *OpenMalaria* using a least 1010 squares approach combined with a Gaussian-Process optimization. The trial described in Zongo et 1011 $al.(2015)^1$ was rebuilt in OM settings listed in Table S4.

	Parameter	Value	Ref.	
Vector specification	orMosquito speciesAn. funestus: 42% indoor, 31% outdoorification[% of total An. gambiae: 14% indoor, 13% outdoor abundance]			
	Total EIR	154	4	
	Seasonality in malaria transmission	An. funestus: Aug Sep Oct Nov 23 16 0 3.1 An. gambiae: Aug Sep Oct Nov	4	
	[mo. EIR]	40 50 16 6.4		
Health System	Access to treatment	Effective coverage E_{14} [%] 50 50 OM 5 day probability E_5 [%] 24.12 24.12	5,6	
	Malaria treatment	First line: Arthemeter-Lumefantrine Treatment failure/Severe malaria: Quinine	5	
Vector	Coverage of ITNs	2006-2008: 14%	5	
Interventions	ITN coverage during trial	27%	3	
Seasonal Malaria Chemoprevention	Timing of interventions	SMC: 15. Aug, 15. Sep, & 15.Oct 2009 Follow-up: 1. Sep, 1.Oct & 1. Nov 2009	3	
-	Protective efficacy of SP+AQ	$E(t) = E0 \ e^{-\left(\frac{t}{L}\right)^k \log(2)}$ Parameter ranges for LHS sampling: Half-life L: [20, 60] days Shape parameter k: [1, 10] Initial efficacy E0: [0.7, 1]	3	

1012 Table S 4: Inputs into OpenMalaria to check adequate parameterization of SMC with SP-AQ.

1013

1014 We used Latin-Hypercube sampling (LHS) to generate 5000 samples of the decay function parameters for 1015 protective efficacy (L, k, E0) within the parameter bounds given in Table S4. The trial was simulated with 1016 these parameters and five seeds per parameter-set for the intervention and control cohort. The protective 1017 efficacy *E* of SMC - SP+AQ in the simulated trial compared to the simulated controls (without intervention) 1018 was extracted by comparing cases per person (cpp) between the intervention group (cpp_{int}) and control 1019 group (cpp_{cont}) over the trial period as follows:

1020
$$E = 1 - \frac{cpp_{int}}{cpp_{cont}}$$
 Equ. S11

1021 The residual sum of squares (RSS) between the protective efficacy given in Zongo et $al.(2015)^3$ and

1022 protective efficacy from OM simulations was extracted and a Gaussian process (GP) regression was trained

1023 to predict the RSS between trial results and OM simulation with the parameters of the protective efficacy

1024 decay.

1025 The true over predicted RSS of the hold-out of 1000 data points is shown in Fig. S11.





1027 Figure S 11: True over predicted RSS of the GP.

1028 The GP was then optimized via non-linear optimization using the augmented Lagrange method (function 1029 gosolnp, R-package Rsolnp). We optimized the mean predicted error \pm - one or two standard deviation of 1030 the residual sum of squares (RSS) between the protective efficacy in Zongo et al.(2015)³ and the OM 1031 simulation output. The parameters of the decay function returned by the optimization process were re-1032 simulated with OM and the RSS extracted (*RSS OM*). The OM simulation resulting in the least RSS was 1033 then selected for further analysis.

Table S 5: Results of the GP optimization. The results of the optimization *RSS optim* is compared with the *predicted (pred.) RSS* by the GP and the RSS extracted from OM simulations (median of 5 seeds) conducted with the respective parameters (*RSS OM*). The solver was restarted 20 times and the number of random parameters generated for every restart was set to n.sim=500.

	kdecay	Half-life	Initial efficacy	RSS optim	RSS pred	RSS OM
Min. RSS before optimisation	6.35	32.5	0.97	-	0.0842	0.0601
mean	5.40	31.3	1.0	0.0538	0.0538	0.0556
Mean +sd	5.29	31.5	1.0	0.0882	0.0542	0.0583
Mean - sd	5.58	31.0	1.0	0.0186	0.0545	0.0538
Mean + 2*sd	5.28	31.5	1.0	0.0895	0.0541	0.0556
Mean – 2*sd	5.62	31.1	1.0	0.0172	0.0544	0.0739

1039 The OM implementation of the best parameter set for the intervention cohort is able to well capture the

1040 protective efficacy described in 3 . The protective efficacy (Figure S12), cumulative hazard (Fig. S13) and

1041 prevalence over time (Fig. S14) provide more insight into the trial results and comparison with OM outputs.

Table S 6: Comparison of trial results of Zongo et al., 2015 ³ **and model outputs using the model specification in Table S4 with the best parameter set.** The compared time-points correspond to the timepoints compared in ³. The difference in prevalence of parasitemia in December 2009 in the untreated cohort are caused by ongoing but decreasing transmission in December (see Figure S3) and unclear definition of data time-point in ³.

	Zongo et al., 2015	OM
		[min, max]
Prevalence of parasitemia [%] in August 2009,	45	45
intervention cohort		[44, 48]
Prevalence of parasitemia [%] in September 2009,	61	60
untreated cohort		[57, 65]
Cumulative hazard for fever with any parasitemia	0.22	0.14
intervention cohort		[0.13, 0.15]
Cumulative hazard for fever with any parasitemia	0.92	1.01
intervention cohort		[0.93, 1.12]
Prevalence of parasitemia [%] in November 2009,	12	19
intervention cohort		[18, 20]
Prevalence of parasitemia [%] in December 2009,	36	46
untreated cohort		[39, 48]

1047











Figure S 14: Prevalence of malaria in children who received SMC with SP-AQ (blue) compared to controls (black) over the trial. The prevalence in the intervention cohort is decreasing with each SMC round every month and then slowly increasing again. At the same time, the prevalence in the control group is increasing with the ongoing malaria transmission season. After the last SMC round, there is an increase of prevalence caused by still ongoing transmission. Simultaneously, the transmission intensity is already decreasing as can be seen in the control cohort prevalence.

WHO. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for
 Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in
 Africa. (World Health Organization, 2012).

Dahal, P. et al. Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated
Plasmodium falciparum malaria: pitfalls and challenges. Malar. J. 16, 430–430 (2017).

1069 3. Zongo, I. et al. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared
1070 with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina
1071 Faso. Antimicrob. Agents Chemother. 59, 4387–4396 (2015).

- 1072 4. Dabire, K. R. et al. Anopheles funestus (Diptera: Culicidae) in a humid savannah area of western
 1073 Burkina Faso: bionomics, insecticide resistance status, and role in malaria transmission. J Med Entomol 44,
 1074 990–7 (2007).
- 1075 5. WHO. World malaria report 2008. (World Health Organization, 2008).
- 1076 6. Penny, M. A. et al. Distribution of malaria exposure in endemic countries in Africa considering 1077 country levels of effective treatment. Malar. J. 14, 384 (2015).

1078